Our Team
o2h ventures team are leaders in the biotech community and have been actively involved as investors, holding various industry positions for over 20 years.
Sunil Shah
CEO
Sunil's Biography
close
Sunil Shah
CEO
Sunil Shah is an entrepreneur having begun his career in the Life Sciences team at PA Consulting. He co-founded Oxygen Healthcare Ltd which was fully acquired by Piramal Enterprises Ltd (BSE: PEL) in 2013. Since this time, Sunil has co-founded the o2h Group, this includes o2h Ventures, an HMRC approved ‘Human Health’ Knowledge Intensive EIS fund; o2h Discovery, a medicinal chemistry research services company and o2h Co-Work Labs, a 2.7Acre Science Park under development in South Cambridge. Sunil has won the UKBAA Angel Investor of the year award in 2019 as well as the OBN Special Recognition Award for his significant contribution in the Life Sciences Industry. He serves on the Board of the BIA as well as Cambridge Angels. Recently, Sunil has also won the CEO of the year award at the Cambridge Independent Science and Technology Awards. He is either Chairman, Non-Executive Director, Board Observer or an investor in over 20 Biotech companies in the UK. Sunil has a degree in Biochemistry from Keele and an MBA from Cambridge University.
Prashant Shah
Managing Partner
Prashant's Biography
close
Prashant Shah
Managing Partner
o2h Ventures was co-founded by Sunil and Prashant Shah in 2013. In the last 3-4 years, they have co-founded four companies with UK-based academics and entrepreneurs, provided consultancy services to five companies, held Chairman or Director level positions in nine companies, built up a portfolio of twenty early-stage investments, and executed early-stage drug discovery research projects for fifteen different companies. In 2013, bucking a pattern of UK Science going to the USA for funding, Sunil and Prashant acted quickly to lead an academic spin out from the USA with promising data in brain cancer and proceeded to run, externally fund and locate that company, Opal Oncology, in the UK. It provided direct hands-on experience of making the scientific decisions and managing the operations of a therapeutics company.
Andy Morley
Principal
Andy's Biography
close
Andy Morley
Principal
Andy is a Medicinal Chemist with over 25 years of experience working in major pharma (Sanofi-Aventis, AZ). He has experience across all discovery phases, having supported five candidates into the clinic. He is the author and inventor of over 55 publications and patents. Andy has been working full-time with o2h Ventures since 2013, leading the scientific evaluation of investments and providing scientific support on key projects within the portfolio. He is currently the CSO of Opal Oncology and had previously served as CSO for two o2h early-stage collaborations.
Gayatri Shah
Human Capital Advisor
Gayatri's Bio
close
Gayatri Shah
Human Capital Advisor
Gayatri Shah has nearly two decades of experience within the search industry, having worked in the UK, USA, and India. She started her search career with Egon Zehnder in India, where she worked for the top 25 Indian Pharma companies, before spending 3 years specialising in finance roles within FTSE 250 organisations at Michael Page in the UK.Prior to founding Tamarind, she was the Principal at BSG Team Ventures (offices in Boston and London), focusing on human capital needs for Venture Capitalist backed biotech start-ups working mainly on cross-border roles between the USA and EU. She is also a board member of Plugin Recruiter, a video recruitment platform start-up based in Cambridge, UK.Gayatri holds a BA (Hons) in Economics from Delhi University and an MSc in Economics from Lancaster University, UK.
Gary Pitts
Compliance Consultant, Tetractys Limited
Gary's Biography
close
Gary Pitts
Compliance Consultant, Tetractys Limited
Gary Pitts MA(Oxon), MA(London), MBA, FInstLM, FCMI, ACSI is a senior compliance professional of 28 year's standing, a former regulator, Head of Compliance for hedge fund Brevan Howard, Head of Compliance for Europe, Mid-East, Africa and Japan for a boutique investment bank. He is a former director of regulated firms in the UK and South Africa and has been an FCA regulated person since 2001, as well as having fulfilled regulated roles in Ireland.Gary is the founder of Tetractys Partners LLP based in London, a compliance consultancy set up in 2013 which acts for asset managers, hedge funds, brokers, fintechs and consumer credit firms, as well as delivering an extensive range of public and in-house technical training courses. He is also founder and CEO of Tetractys Ireland Limited, its Irish affiliate offering similar services to the Irish market.
Dr Chris Torrance
Independent Representative of the Investment Advisory Panel
Dr Chris Torrance Biography
close
Dr Chris Torrance
Independent Representative of the Investment Advisory Panel
Chris is a cancer researcher and entrepreneur. In 2007 he founded Horizon Discovery to translate advances in human genome editing into a range of research tools and services to accelerate the discovery of new and improved ‘Personalized Medicines’, including the identification of novel drug targets for pharmaceutical development. By 2014 Chris and his colleagues had built Horizon into the fastest growing Biotech company in the UK. In the same year, the company listed on the London Stock Exchange with over 100 commercial and scientific staff and significant deal flow with the pharmaceutical Industry, for which Horizon received the Queens Award for International Trade in 2012. Chris completed his post-doctoral training in the laboratory of Professor Bert Vogelstein at the Johns Hopkins University (U.S.A).
Catherine Beech
Independent Representative to the Investment Advisory Panel
Catherine Beech Biography
close
Catherine Beech
Independent Representative to the Investment Advisory Panel
Catherine has over 25 years of experience in biotech, pharmaceutical and as a venture investor. She is currently the CEO of Exonate for which she was one of the founders leading the spin-out from Nottingham University. Catherine has a degree in medicine
from Birmingham University and in 2008 was awarded the OBE for services to technology and innovation.
Cengiz Tarhan
Independent Representative of the Investment Advisory Panel
Cengiz Tarhan Biography
close
Cengiz Tarhan
Independent Representative of the Investment Advisory Panel
Cengiz set up FreeMedic PLC in 1993 which he grew over 25 years and is now known as UCL Business PLC, one of the most prolific and successful technology groups in the UK serving UCL and its associated partner hospitals. Over those years Cengiz was directly involved in many licenses and spinouts including PolyMASC Pharmaceuticals PLC, one of the first university spinouts to float on the London AIM in 1995, Medic to Medic Ltd which was sold to Informa PLC in 2005 and Stanmore Implants Wordwide Limited which was acquired by Abingworth and MDY Healthcare in February 2008. More recently UCLB has been at the vanguard of creating the most promising cancer and gene therapy biotechs in the UK including three.
R G Boyle
Independent Representative of the Investment Advisory Panel
Robert's Biography
close
R G Boyle
Independent Representative of the Investment Advisory Panel
R G Boyle is a founder and the CEO of Sentinel Oncology Ltd, a company dedicated towards the discovery of novel small molecules for the treatment of unmet medical needs. Robert is a medicinal chemist by background with over twenty-five years’ industrial experience. He has held positions at Pfizer (1993-1997); Cambridge Discovery Chemistry (1997-2000); Millennium Pharmaceuticals (200-2003); Astex Therapeutics (2003-2005) & Sentinel Oncology (2005-present). As CEO & founder of Sentinel Oncology, he has successfully raised multiple rounds of funding, built a pipeline of small molecule drug assets and secured multiple licensing deals with Biotech and Pharma. Sentinel has been the recipient of numerous awards & grants for innovation and Robert is a named inventor on over 50 patents & publications describing the discovery and use of small molecules for the treatment of unmet medical needs.
Tim Sparey
Independent Representative of the Investment Advisory Panel
Tim Sparey Biography
close
Tim Sparey
Independent Representative of the Investment Advisory Panel
Tim is an experienced biotech and pharmaceutical leader with a strong track record in executive (Exec Chair, CEO, CBO) and board roles. A founder with over 40 patents and publications, he has successfully led companies through key growth phases, securing over $6 billion in deals, including M&A, licensing, and collaborations. His expertise spans drug discovery, business development, fundraising, and strategic advisory across oncology, CNS, cardiometabolic, AI/ML, inflammation, and vaccines. Tim is known for pioneering innovative R&D approaches and building high-performing cross-functional teams to drive biotech success.
Chris Reid
Venture Partner
Chris's Biography
close
Chris Reid
Venture Partner
Chris Reid worked in the City for 17 years as a successful equity research analyst and a fund manager. Amongst other achievements, he built a UK Income fund from scratch to be one of the best performing funds in the sector (150% total return in six years) with over £1bn AUM. Prior to joining the City, he spent 6 years as a Technology Consultant at PA Consultants, focusing on evaluation and support of new products and businesses. He has first-hand experience of over 200 businesses in all industries from mining to high-technology manufacturing across the UK, US and Europe and a deep understanding of the financial, strategic and operational factors that must all come together to ensure a successful, financially rewarding investment. He has a Cambridge MA in Natural Sciences (Materials Science) and an MBA from London Business School.
Dr Nigel Pitchford
Venture Partner
close
Dr Nigel Pitchford
Venture Partner
Nigel is the CEO of Ieso Digital Health Limited - the world leading digital health company specialising in evidence-based online Cognitive Behavioural Therapy (CBT). Prior to joining Ieso he was the Chief Investment Officer for Touchstone Innovations plc and was responsible for all of the Group's investment activities, which were concentrated on UK-based start-ups in the Healthcare and Technology sectors. During his tenure, the active venture portfolio grew to some 50 companies with corresponding value growth in excess of £350m. Previously he had been a partner at DFJ Esprit and 3i and was an active investor across Europe and the US. His previous investments include Domantis (sold to GSK), Arakis (sold to Sosei Pharma), Apatech (sold to Baxter), Endosense (sold to St Jude), EUSA Pharma (sold to Jazz), Horizon Discovery (AIM: HZD) and Oxford Immunotec (NASDAQ: OXFD).
Jeff Roix
Venture Partner
Jeff's Biography
close
Jeff Roix
Venture Partner
Jeff is a scientist and biotech entrepreneur with over 15 years of experience in discovering medicines. Most recently, he was founder and CEO of NeoPhore Ltd, a UK cancer immunotherapy biotech making small-molecule drugs in DNA damage repair. Prior to that, he worked as COO to establish PhoreMost, a Cambridge University spinout company making therapeutics for “undruggable” targets across many diseases.Jeff’s longer experience in translational and early drug discovery spans US organisations across venture, biotech, pharma and academic science. Jeff obtained his bachelors from the Harvard Extension School, with further training and expertise in the genetics and cell biology of cancer, diabetes and metabolic disease.
Riddhi Ahuja
Senior Fund Operations Manager
Riddhi's Biography
close
Riddhi Ahuja
Senior Fund Operations Manager
Riddhi is the Senior Fund Operations Manager at o2h ventures and also the EA to CEO. She acts as a liaison for fund-related matters and looks out for deal flow that comes in from prospective investee companies. She has extensive experience as an operations and international business manager in a reputed manufacturing firm. Riddhi has expertise in the field of business administration, marketing, finance and international business management. She has a bachelor’s degree in Business Administration from ICFAI university..
Ajit Singh Guller
Marketing Manager
Ajit's Biography
close
Ajit Singh Guller
Marketing Manager
As o2h Group’s Marketing Manager, Ajit leads a team of bright marketing professionals focused on strengthening the o2h group brand in the industry and spotting business growth opportunities. Ajit is responsible for brand marketing, advertising and research, content and digital marketing, business analytics, PR and communications.Prior to joining o2h Group, Ajit worked as a digital marketer for two SME tech companies with global client bases and a seed stage ecommerce startup. He is an experienced professional with an eye for design, user experience and behaviour, and digital analytics.
Chris White
Vice President, Business Development
close
Chris White
Vice President, Business Development
Chris leads fundraising for the o2h human health EIS and SEIS funds, bringing a wealth of experience in business development across the financial services sector. Before joining o2h Ventures, he worked with an independent provider specialising in EIS/SEIS analysis and tax-advantaged investments. His diverse background includes roles in financial media and renewable energy financing. Chris holds a degree in French and European Studies from Aston University.
Juhi Shah
Marketing Manager - o2h Ventures
Juhi's biography
close
Juhi Shah
Marketing Manager - o2h Ventures
Juhi is the Marketing Manager at o2h Ventures, overseeing the entire marketing lifecycle. She is responsible for curating various marketing content which includes blogs, social media, and websites to generate organic as well as paid traffic and contribute to the company’s revenue. She has previous experience working in the financial and accounting sectors prior to joining o2h Ventures. She has a master's degree in business administration from PDEU University.
Shubham Tiwari
Deal Flow Manager
close
Shubham Tiwari
Deal Flow Manager
Shubham holds the position of Deal Flow Manager at o2h Ventures, where he plays a vital role in the management and expansion of our investment portfolio. His educational background includes a master's degree in biotechnology, which provides him with a strong domain knowledge essential for evaluating the feasibility of investment opportunities. He has prior experience as a healthcare research analyst, where he developed his skills in competitive intelligence, market estimation, and segmentation.
Speak to a member of our team